ALTERITY THERAPEUTICS LIMITED - Announcements

0.00%

1.1¢

Market Cap $100.4M

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ATH	Change in substantial holding		23/05/25	459.93KB	Share
ATH	Alterity Prominently Featured at International MSA Congress		12/05/25	248.27KB	Share
ATH	Change in substantial holding		12/05/25	443.5KB	Share
ATH	Alterity Phase 2 Data to be Featured at MSA Congress		07/05/25	208.38KB	Share
ATH	Alterity Granted U.S. FDA Fast Track Designation for ATH434	PRICE SENSITIVE	05/05/25	233.86KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	356.37KB	Share
ATH	Change of Director's Interest Notice x 3		29/04/25	20.43KB	Share
ATH	Alterity Phase 2 Presentation at MSA Symposium 2025		28/04/25	1.12MB	Share
ATH	New Options - Top 20 Holders and Range of Units		22/04/25	83.18KB	Share
ATH	Application for quotation of securities - ATH		22/04/25	17.96KB	Share
ATH	Updated Corporate Presentation		22/04/25	1.25MB	Share
ATH	Options Prospectus	PRICE SENSITIVE	17/04/25	418.67KB	Share
ATH	Alterity Phase 2 Presentation at AAN 2025	PRICE SENSITIVE	10/04/25	910.47KB	Share
ATH	Alterity Presents Encouraging New Phase 2 Data in MSA	PRICE SENSITIVE	10/04/25	214.77KB	Share
ATH	Change of Director's Interest Notice x 3		09/04/25	19.35KB	Share
ATH	Becoming a substantial holder		08/04/25	93.51KB	Share
ATH	Change in substantial holding		08/04/25	387.78KB	Share
ATH	Completion of Placement		07/04/25	193.24KB	Share
ATH	Notice Under Section 708A		07/04/25	91.2KB	Share
ATH	Application for quotation of securities - ATH		07/04/25	15.87KB	Share
ATH	Alterity to Deliver Oral Presentation of ATH434 Trial at AAN		03/04/25	201.52KB	Share
ATH	Results of Meeting		31/03/25	25.59KB	Share
ATH	Alterity Completes Last Patient Visit in Open-Label Trial	PRICE SENSITIVE	27/03/25	200.8KB	Share
ATH	Ceasing to be a substantial holder		24/03/25	754.11KB	Share
ATH	Application for quotation of securities - ATH		14/03/25	15.63KB	Share
ATH	Becoming a substantial holder		13/03/25	944.45KB	Share
ATH	Notice of Extraordinary General Meeting/Proxy Form		28/02/25	469.1KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/25	709.07KB	Share
ATH	Proposed issue of securities - ATH		24/02/25	16.95KB	Share
ATH	Change in substantial holding		19/02/25	476.17KB	Share
ATH	Notice Under Section 708A		17/02/25	105.51KB	Share
ATH	Application for quotation of securities - ATH		17/02/25	15.97KB	Share
ATH	Proposed issue of securities - ATH		10/02/25	19.4KB	Share
ATH	Alterity raises A$40m to Advance ATH434 Development in MSA	PRICE SENSITIVE	10/02/25	182.76KB	Share
ATH	Ceasing to be a substantial holder		07/02/25	326.38KB	Share
ATH	Trading Halt	PRICE SENSITIVE	06/02/25	272.28KB	Share
ATH	Becoming a substantial holder		06/02/25	403.04KB	Share
ATH	Disclosure under Takeovers Panel GN 20		05/02/25	308.67KB	Share
ATH	Change in substantial holding		05/02/25	514.11KB	Share
ATH	Notice Under Section 708A		04/02/25	103.02KB	Share
ATH	Application for quotation of securities - ATH		04/02/25	15.67KB	Share
ATH	Proposed issue of securities - ATH		03/02/25	15.15KB	Share
ATH	Alterity Raises Funds for ATH434 BD and Clinical Activities	PRICE SENSITIVE	03/02/25	196.99KB	Share
ATH	Application for quotation of securities - ATH		30/01/25	15.75KB	Share
ATH	ATH434-201 Phase 2 Topline Results Presentation		30/01/25	1.91MB	Share
ATH	Positive ATH434 Phase 2 Results Led By Clinical Efficacy	PRICE SENSITIVE	30/01/25	263.37KB	Share
ATH	Trading Halt	PRICE SENSITIVE	28/01/25	273.13KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/25	396.94KB	Share
ATH	Application for quotation of securities - ATH		22/01/25	15.63KB	Share
ATH	ATH shareholder newsletter January 2025		17/01/25	174.29KB	Share
ATH	Change of Director's Interest Notice x 4		06/01/25	304.8KB	Share
ATH	Notification regarding unquoted securities - ATH		31/12/24	18.56KB	Share
ATH	Alterity Announces Completion of Phase 2 Clinical Trial	PRICE SENSITIVE	04/12/24	203KB	Share
ATH	Results of Meeting		22/11/24	156.91KB	Share
ATH	Presentation to Annual General Meeting		22/11/24	1.31MB	Share
ATH	Chairman's Address 2024 Annual General Meeting		22/11/24	131.24KB	Share
ATH	Change of Company Secretary		19/11/24	136.01KB	Share
ATH	ATH Presentation Tracking MSA Progression at Intl Symposium		12/11/24	237.86KB	Share
ATH	Alterity Announces Publication On ATH434 Mechanism of Action		06/11/24	223.7KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	388.2KB	Share
ATH	Notice of Annual General Meeting		23/10/24	525.08KB	Share
ATH	ATH to Participate in 2024 Maxim Healthcare Virtual Summit		14/10/24	136.29KB	Share
ATH	Alterity Presents Data Describing Neuroprotection of ATH434		11/10/24	200.85KB	Share
ATH	Change of Share Registry		04/10/24	197.46KB	Share
ATH	Alterity Data Presentations at MDS Congress Raises Profile		02/10/24	251.42KB	Share
ATH	Alterity Therapeutics Filed Form 20-F and XBRL data with SEC		30/09/24	174.92KB	Share
ATH	ATH Appoints Abby Macnish Niven as Chief Financial Officer		30/09/24	172.97KB	Share
ATH	Appendix 4G		26/09/24	260.85KB	Share
ATH	Corporate Governance Statement		26/09/24	161.06KB	Share
ATH	Annual Report 2024		26/09/24	1.4MB	Share
ATH	Alterity to Deliver Multiple Presentations at MDS Congress		23/09/24	270.78KB	Share
ATH	Change of Director's Interest Notice - BM / PM		20/09/24	195.75KB	Share
ATH	Notification of cessation of securities - ATH		02/09/24	12.92KB	Share
ATH	Appendix 4E Preliminary Final Report	PRICE SENSITIVE	29/08/24	327.59KB	Share
ATH	Notification of cessation of securities - ATH		01/08/24	12.95KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	734.22KB	Share
ATH	Alterity Therapeutics to Present at MST Financial Webinar		24/07/24	158.86KB	Share
ATH	Notice Under Section 708A		19/07/24	230.29KB	Share
ATH	Application for quotation of securities - ATH		19/07/24	15.69KB	Share
ATH	Proposed issue of securities - ATH		18/07/24	15.09KB	Share
ATH	Positive Interim Data from ATH434-202 Phase 2 Clinical Trial	PRICE SENSITIVE	17/07/24	261.82KB	Share
ATH	Trading Halt	PRICE SENSITIVE	15/07/24	215.69KB	Share
ATH	Notification regarding unquoted securities - ATH		28/06/24	23.53KB	Share
ATH	Alterity to Present at Hidden Gems in Life Sciences Webinar		13/06/24	160.16KB	Share
ATH	Webcast Today - New Data from bioMUSE Natural History Study		30/05/24	3.1MB	Share
ATH	Notification of cessation of securities - ATH		21/05/24	12.96KB	Share
ATH	Phase 2 DMC Recommends Continuing Clinical Trial as Planned		08/05/24	206.13KB	Share
ATH	Ceasing to be a substantial holder		08/05/24	578.33KB	Share
ATH	Change in substantial holding		03/05/24	452.43KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	2.04MB	Share
ATH	Application for quotation of securities - ATH		29/04/24	15.6KB	Share
ATH	Alterity Presents New Data on ATH434		29/04/24	223.27KB	Share
ATH	Change in substantial holding		18/04/24	416.97KB	Share
ATH	Alterity Parkinson's and MSA Data Featured at AAN Meeting		17/04/24	279.47KB	Share
ATH	Application for quotation of securities - ATH		15/04/24	15.77KB	Share
ATH	Options Prospectus		12/04/24	396.89KB	Share
ATH	Results of Extraordinary General Meeting		12/04/24	178.79KB	Share
ATH	Alterity to Present New ATH434 Data at Orphan Drug Congress		10/04/24	266.37KB	Share
ATH	Alterity Receives a $3.9 million R&D Tax Incentive Refund	PRICE SENSITIVE	26/03/24	148.62KB	Share
ATH	Change in substantial holding		25/03/24	1.5MB	Share

ATH Change in substantial holding
23/05/25		459.93KB	Share
ATH Alterity Prominently Featured at International MSA Congress
12/05/25		248.27KB	Share
ATH Change in substantial holding
12/05/25		443.5KB	Share
ATH Alterity Phase 2 Data to be Featured at MSA Congress
07/05/25		208.38KB	Share
ATH Alterity Granted U.S. FDA Fast Track Designation for ATH434
05/05/25	PRICE SENSITIVE	233.86KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	356.37KB	Share
ATH Change of Director's Interest Notice x 3
29/04/25		20.43KB	Share
ATH Alterity Phase 2 Presentation at MSA Symposium 2025
28/04/25		1.12MB	Share
ATH New Options - Top 20 Holders and Range of Units
22/04/25		83.18KB	Share
ATH Application for quotation of securities - ATH
22/04/25		17.96KB	Share
ATH Updated Corporate Presentation
22/04/25		1.25MB	Share
ATH Options Prospectus
17/04/25	PRICE SENSITIVE	418.67KB	Share
ATH Alterity Phase 2 Presentation at AAN 2025
10/04/25	PRICE SENSITIVE	910.47KB	Share
ATH Alterity Presents Encouraging New Phase 2 Data in MSA
10/04/25	PRICE SENSITIVE	214.77KB	Share
ATH Change of Director's Interest Notice x 3
09/04/25		19.35KB	Share
ATH Becoming a substantial holder
08/04/25		93.51KB	Share
ATH Change in substantial holding
08/04/25		387.78KB	Share
ATH Completion of Placement
07/04/25		193.24KB	Share
ATH Notice Under Section 708A
07/04/25		91.2KB	Share
ATH Application for quotation of securities - ATH
07/04/25		15.87KB	Share
ATH Alterity to Deliver Oral Presentation of ATH434 Trial at AAN
03/04/25		201.52KB	Share
ATH Results of Meeting
31/03/25		25.59KB	Share
ATH Alterity Completes Last Patient Visit in Open-Label Trial
27/03/25	PRICE SENSITIVE	200.8KB	Share
ATH Ceasing to be a substantial holder
24/03/25		754.11KB	Share
ATH Application for quotation of securities - ATH
14/03/25		15.63KB	Share
ATH Becoming a substantial holder
13/03/25		944.45KB	Share
ATH Notice of Extraordinary General Meeting/Proxy Form
28/02/25		469.1KB	Share
ATH Half Yearly Report and Accounts
28/02/25	PRICE SENSITIVE	709.07KB	Share
ATH Proposed issue of securities - ATH
24/02/25		16.95KB	Share
ATH Change in substantial holding
19/02/25		476.17KB	Share
ATH Notice Under Section 708A
17/02/25		105.51KB	Share
ATH Application for quotation of securities - ATH
17/02/25		15.97KB	Share
ATH Proposed issue of securities - ATH
10/02/25		19.4KB	Share
ATH Alterity raises A$40m to Advance ATH434 Development in MSA
10/02/25	PRICE SENSITIVE	182.76KB	Share
ATH Ceasing to be a substantial holder
07/02/25		326.38KB	Share
ATH Trading Halt
06/02/25	PRICE SENSITIVE	272.28KB	Share
ATH Becoming a substantial holder
06/02/25		403.04KB	Share
ATH Disclosure under Takeovers Panel GN 20
05/02/25		308.67KB	Share
ATH Change in substantial holding
05/02/25		514.11KB	Share
ATH Notice Under Section 708A
04/02/25		103.02KB	Share
ATH Application for quotation of securities - ATH
04/02/25		15.67KB	Share
ATH Proposed issue of securities - ATH
03/02/25		15.15KB	Share
ATH Alterity Raises Funds for ATH434 BD and Clinical Activities
03/02/25	PRICE SENSITIVE	196.99KB	Share
ATH Application for quotation of securities - ATH
30/01/25		15.75KB	Share
ATH ATH434-201 Phase 2 Topline Results Presentation
30/01/25		1.91MB	Share
ATH Positive ATH434 Phase 2 Results Led By Clinical Efficacy
30/01/25	PRICE SENSITIVE	263.37KB	Share
ATH Trading Halt
28/01/25	PRICE SENSITIVE	273.13KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
24/01/25	PRICE SENSITIVE	396.94KB	Share
ATH Application for quotation of securities - ATH
22/01/25		15.63KB	Share
ATH ATH shareholder newsletter January 2025
17/01/25		174.29KB	Share
ATH Change of Director's Interest Notice x 4
06/01/25		304.8KB	Share
ATH Notification regarding unquoted securities - ATH
31/12/24		18.56KB	Share
ATH Alterity Announces Completion of Phase 2 Clinical Trial
04/12/24	PRICE SENSITIVE	203KB	Share
ATH Results of Meeting
22/11/24		156.91KB	Share
ATH Presentation to Annual General Meeting
22/11/24		1.31MB	Share
ATH Chairman's Address 2024 Annual General Meeting
22/11/24		131.24KB	Share
ATH Change of Company Secretary
19/11/24		136.01KB	Share
ATH ATH Presentation Tracking MSA Progression at Intl Symposium
12/11/24		237.86KB	Share
ATH Alterity Announces Publication On ATH434 Mechanism of Action
06/11/24		223.7KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	388.2KB	Share
ATH Notice of Annual General Meeting
23/10/24		525.08KB	Share
ATH ATH to Participate in 2024 Maxim Healthcare Virtual Summit
14/10/24		136.29KB	Share
ATH Alterity Presents Data Describing Neuroprotection of ATH434
11/10/24		200.85KB	Share
ATH Change of Share Registry
04/10/24		197.46KB	Share
ATH Alterity Data Presentations at MDS Congress Raises Profile
02/10/24		251.42KB	Share
ATH Alterity Therapeutics Filed Form 20-F and XBRL data with SEC
30/09/24		174.92KB	Share
ATH ATH Appoints Abby Macnish Niven as Chief Financial Officer
30/09/24		172.97KB	Share
ATH Appendix 4G
26/09/24		260.85KB	Share
ATH Corporate Governance Statement
26/09/24		161.06KB	Share
ATH Annual Report 2024
26/09/24		1.4MB	Share
ATH Alterity to Deliver Multiple Presentations at MDS Congress
23/09/24		270.78KB	Share
ATH Change of Director's Interest Notice - BM / PM
20/09/24		195.75KB	Share
ATH Notification of cessation of securities - ATH
02/09/24		12.92KB	Share
ATH Appendix 4E Preliminary Final Report
29/08/24	PRICE SENSITIVE	327.59KB	Share
ATH Notification of cessation of securities - ATH
01/08/24		12.95KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	734.22KB	Share
ATH Alterity Therapeutics to Present at MST Financial Webinar
24/07/24		158.86KB	Share
ATH Notice Under Section 708A
19/07/24		230.29KB	Share
ATH Application for quotation of securities - ATH
19/07/24		15.69KB	Share
ATH Proposed issue of securities - ATH
18/07/24		15.09KB	Share
ATH Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
17/07/24	PRICE SENSITIVE	261.82KB	Share
ATH Trading Halt
15/07/24	PRICE SENSITIVE	215.69KB	Share
ATH Notification regarding unquoted securities - ATH
28/06/24		23.53KB	Share
ATH Alterity to Present at Hidden Gems in Life Sciences Webinar
13/06/24		160.16KB	Share
ATH Webcast Today - New Data from bioMUSE Natural History Study
30/05/24		3.1MB	Share
ATH Notification of cessation of securities - ATH
21/05/24		12.96KB	Share
ATH Phase 2 DMC Recommends Continuing Clinical Trial as Planned
08/05/24		206.13KB	Share
ATH Ceasing to be a substantial holder
08/05/24		578.33KB	Share
ATH Change in substantial holding
03/05/24		452.43KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	2.04MB	Share
ATH Application for quotation of securities - ATH
29/04/24		15.6KB	Share
ATH Alterity Presents New Data on ATH434
29/04/24		223.27KB	Share
ATH Change in substantial holding
18/04/24		416.97KB	Share
ATH Alterity Parkinson's and MSA Data Featured at AAN Meeting
17/04/24		279.47KB	Share
ATH Application for quotation of securities - ATH
15/04/24		15.77KB	Share
ATH Options Prospectus
12/04/24		396.89KB	Share
ATH Results of Extraordinary General Meeting
12/04/24		178.79KB	Share
ATH Alterity to Present New ATH434 Data at Orphan Drug Congress
10/04/24		266.37KB	Share
ATH Alterity Receives a $3.9 million R&D Tax Incentive Refund
26/03/24	PRICE SENSITIVE	148.62KB	Share
ATH Change in substantial holding
25/03/24		1.5MB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $100.4M

Open	High	Low	Value	Volume
1.0¢	1.1¢	1.0¢	$60.81K	5.737M

Buyers (Bids)

No.	Vol.	Price($)
37	16255465	1.0¢

Sellers (Offers)

Price($)	Vol.	No.
1.1¢	1643984	2

View Market Depth

No.	Vol.	Price($)
32	9305965	0.010
30	26756594	0.009
15	25470226	0.008
12	23772392	0.007
15	24953518	0.006

Price($)	Vol.	No.
0.011	1643984	2
0.012	20418298	32
0.013	7744325	14
0.014	13188180	7
0.015	2059976	9

Last trade - 16.10pm 13/06/2025 (20 minute delay)

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available